help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Godsland, I. F.
Right arrow Articles by Wynn, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Godsland, I. F.
Right arrow Articles by Wynn, V.

Journal of Clinical Endocrinology & Metabolism, Vol 74, 64-70, Copyright © 1992 by Endocrine Society

ARTICLES

Insulin resistance, secretion, and metabolism in users of oral contraceptives

IF Godsland, C Walton, C Felton, A Proudler, A Patel and V Wynn
Wynn Institute for Metabolic Research, St. John's Wood, London, England.

Studies of insulin employing the oral glucose tolerance test demonstrate marked differences between the effects of different oral contraceptives, but provide little insight into the underlying disturbances. We investigated the metabolic basis of these disturbances by computer modelling of iv glucose tolerance test glucose, insulin, and C-peptide concentration profiles. Insulin resistance, secretion, and metabolism were evaluated in 296 oral contraceptive users and 95 nonusers. Four estrogen/progestin combinations, with similar estrogen but differing progestin contents, and 1 progestin-only formulation were studied. Effects on iv glucose tolerance test glucose, insulin, and C- peptide concentrations varied according to progestin content, with levonorgestrel-containing combinations having the greatest effect, followed by desogestrel and norethindrone. However, these formulations increased insulin resistance to a similar extent. The progestin-only formulation did not affect insulin resistance. Levonorgestrel combinations increased second phase pancreatic insulin secretion by 60- 90%, but did not affect the insulin half-life. The desogestrel combination increased the insulin half-life by 28%, but did not affect insulin secretion. The effects of different combined oral contraceptives on glucose tolerance test glucose, insulin, and C- peptide concentration profiles appears to be due to a combination of estrogen-induced insulin resistance and progestin-associated changes in insulin half-life.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
R. H. Willemsen, R. W. J. Leunissen, T. Stijnen, and A. C. S. Hokken-Koelega
Prematurity Is Not Associated with Reduced Insulin Sensitivity in Adulthood
J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1695 - 1700.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. A. Frempong, M. Ricks, S. Sen, and A. E. Sumner
Effect of Low-Dose Oral Contraceptives on Metabolic Risk Factors in African-American Women
J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2097 - 2103.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Palomba, A. Falbo, T. Russo, F. Manguso, A. Tolino, F. Zullo, P. De Feo, and F. Orio Jr.
Insulin Sensitivity after Metformin Suspension in Normal-Weight Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3128 - 3135.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. M. Hedderson, A. Ferrara, M. A. Williams, V. L. Holt, and N. S. Weiss
Androgenicity of Progestins in Hormonal Contraceptives and the Risk of Gestational Diabetes Mellitus
Diabetes Care, May 1, 2007; 30(5): 1062 - 1068.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. J. Gallagher, K. L. Keene, J. C. Mychaleckyj, C. D. Langefeld, J. N. Hirschhorn, B. E. Henderson, C. J. Gordon, B. I. Freedman, S. S. Rich, D. W. Bowden, et al.
Investigation of the Estrogen Receptor-{alpha} Gene With Type 2 Diabetes and/or Nephropathy in African-American and European-American Populations
Diabetes, March 1, 2007; 56(3): 675 - 684.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Sam, R. S. Legro, P. A. Essah, T. Apridonidze, and A. Dunaif
Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome
PNAS, May 2, 2006; 103(18): 7030 - 7035.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Sam, R. S. Legro, R. Bentley-Lewis, and A. Dunaif
Dyslipidemia and Metabolic Syndrome in the Sisters of Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4797 - 4802.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
J. Vrbikova and D. Cibula
Combined oral contraceptives in the treatment of polycystic ovary syndrome
Hum. Reprod. Update, May 1, 2005; 11(3): 277 - 291.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
K.-C. Leung, G. Johannsson, G. M. Leong, and K. K. Y. Ho
Estrogen Regulation of Growth Hormone Action
Endocr. Rev., October 1, 2004; 25(5): 693 - 721.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
V. De Leo, A. la Marca, and F. Petraglia
Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
Endocr. Rev., October 1, 2003; 24(5): 633 - 667.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Cagnacci, A. M. Paoletti, A. Renzi, M. Orru, M. Pilloni, G. B. Melis, and A. Volpe
Glucose Metabolism and Insulin Resistance in Women with Polycystic Ovary Syndrome during Therapy with Oral Contraceptives Containing Cyproterone Acetate or Desogestrel
J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3621 - 3625.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
L. A. Stadtmauer, B. C. Wong, and S. Oehninger
Should patients with polycystic ovary syndrome be treated with metformin?: Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction
Hum. Reprod., December 1, 2002; 17(12): 3016 - 3026.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
V. Jayagopal, E. S. Kilpatrick, P. E. Jennings, D. A. Hepburn, and S. L. Atkin
Biological Variation of Homeostasis Model Assessment-Derived Insulin Resistance in Type 2 Diabetes
Diabetes Care, November 1, 2002; 25(11): 2022 - 2025.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Bagis, A. Gokcel, H. B. Zeyneloglu, E. Tarim, E. B. Kilicdag, and B. Haydardedeoglu
The Effects of Short-Term Medroxyprogesterone Acetate and Micronized Progesterone on Glucose Metabolism and Lipid Profiles in Patients with Polycystic Ovary Syndrome: A Prospective Randomized Study
J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4536 - 4540.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
C. Kim, D. S. Siscovick, S. Sidney, C. E. Lewis, C. I. Kiefe, and T. D. Koepsell
Oral Contraceptive Use and Association With Glucose, Insulin, and Diabetes in Young Adult Women: The CARDIA Study
Diabetes Care, June 1, 2002; 25(6): 1027 - 1032.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. S. Legro, R. Bentley-Lewis, D. Driscoll, S. C. Wang, and A. Dunaif
Insulin Resistance in the Sisters of Women with Polycystic Ovary Syndrome: Association with Hyperandrogenemia Rather Than Menstrual Irregularity
J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2128 - 2133.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
I. R. Pirwany, N. Sattar, I. A. Greer, C. J. Packard, and R. Fleming
Supraphysiological concentrations of estradiol in menopausal women given repeated implant therapy do not adversely affect lipid profiles
Hum. Reprod., March 1, 2002; 17(3): 825 - 829.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
D. Cibula, M. Fanta, M. Hill, G. Sindelka, J. Skrha, and J. Zivny
Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin
Hum. Reprod., January 1, 2002; 17(1): 76 - 82.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C. G. Solomon, F. B. Hu, A. Dunaif, J. Rich-Edwards, W. C. Willett, D. J. Hunter, G. A. Colditz, F. E. Speizer, and J. E. Manson
Long or Highly Irregular Menstrual Cycles as a Marker for Risk of Type 2 Diabetes Mellitus
JAMA, November 21, 2001; 286(19): 2421 - 2426.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. P. Goldstone, E. L. Thomas, A. E. Brynes, J. D. Bell, G. Frost, N. Saeed, J. V. Hajnal, J. K. Howard, A. Holland, and S. R. Bloom
Visceral Adipose Tissue and Metabolic Complications of Obesity Are Reduced in Prader-Willi Syndrome Female Adults: Evidence for Novel Influences on Body Fat Distribution
J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4330 - 4338.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
V.L. Armstrong, M.I. Wiggam, C.N. Ennis, B. Sheridan, A.I. Traub, A.B. Atkinson, and P.M. Bell
Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate
QJM, January 1, 2001; 94(1): 31 - 37.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
J. Ribstein, J.-M. Halimi, G. du Cailar, and A. Mimran
Renal Characteristics and Effect of Angiotensin Suppression in Oral Contraceptive Users
Hypertension, January 1, 1999; 33(1): 90 - 95.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
E. J. Giltay, J. M. H. Elbers, L. J. G. Gooren, J. J. Emeis, T. Kooistra, H. Asscheman, and C. D. A. Stehouwer
Visceral Fat Accumulation Is an Important Determinant of PAI-1 Levels in Young, Nonobese Men and Women : Modulation by Cross-Sex Hormone Administration
Arterioscler Thromb Vasc Biol, November 1, 1998; 18(11): 1716 - 1722.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
R. M. Watanabe, G. M. Steil, and R. N. Bergman
Critical evaluation of the combined model approach for estimation of prehepatic insulin secretion
Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E172 - E183.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. Dunaif
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis
Endocr. Rev., December 1, 1997; 18(6): 774 - 800.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Nader, M. G. Riad-Gabriel, and M. F. Saad
The Effect of a Desogestrel-Containing Oral Contraceptive on Glucose Tolerance and Leptin Concentrations in Hyperandrogenic Women
J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3074 - 3077.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
K. L. Thornton, R. A. DeFronzo, R. S. Sherwin, and M. P. Diamond
Micronized Estradiol and Progesterone: Effects on Carbohydrate Metabolism in Reproductive-Age Women
Reproductive Sciences, July 1, 1995; 2(4): 643 - 652.
[Abstract] [PDF]

Home page
 Arch Intern MedHome page
N. M. Kaplan
The Treatment of Hypertension in Women
Arch Intern Med, March 27, 1995; 155(6): 563 - 567.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1992 by The Endocrine Society